

Governing Council Sixty-second Session **GC/62/16** 17/04/2020

Monday 11 and Tuesday 12 May 2020 To be held by webconference (due to COVID-19 pandemic and travel restrictions)

APPOINTMENT OF NEW MEMBERS OF THE SCIENTIFIC COUNCIL

1. In accordance with Article VI of the Statute and Resolution <u>GC/58/R17</u>, the term of office of five members of the Scientific Council, namely Drs Adèle Green (Australia), Atsushi Ochiai (Japan), Roberto Salgado (Belgium), Pilar Sánchez Gómez (Spain) and Simon Tavaré (UK) will be completed with the 2020 meeting of the Governing Council.

2. For the information of the Council, this leaves the following 21 members (11 women and 10 men) still serving on the Scientific Council: Drs Salha Bujassoum Al Bader (Qatar), Jacqueline Clavel (France), Christine Friedenreich (Canada), Maria Sibilia (Austria) and João Viola (Brazil) until 2021; Drs Hendriek Boshuizen (Netherlands), James Robert Cerhan (USA), Janne Mikael Pitkäniemi (Finland), Sabine Rohrmann (Switzerland), Anne Tjønneland (Denmark) and Kazem Zendehdel, Iran (Islamic Republic of) until 2022; and Drs Karima Bendahhou (Morocco), Tone Bjørge (Norway), Gunilla Enblad (Sweden), William Gallagher (Ireland), Ulrike Haug (Germany), Sergey Ivanov (Russian Federation), Ravi Mehrotra (India), Péter Nagy (Hungary), Jong Bae Park (Republic of Korea) and Pietro Pichierri (Italy) until 2023.

3. The areas of expertise of those members remaining on the Scientific Council are provided below for consideration by the Governing Council in making its selection of new Scientific Council members from among the nominations.

Name	Country	Term of office	Gender	Field of expertise
Salha M. Bujassoum Al Bader	Qatar	2018 – 2021	F	Oncology, breast cancer, cancer screening
Jacqueline Clavel	France	2018 – 2021	F	Environmental epidemiology, childhood cancer, cancer registries
Christine Friedenreich	Canada	2018 – 2021	F	Cancer etiology, prevention and survival, physical activity
Maria Sibilia	Austria	2018 – 2021	F	Molecular medicine, tumour immunology, inflammation
João P.B. Viola	Brazil	2018 – 2021	Μ	Tumour immunology, cancer cell transformation
Hendriek Boshuizen	Netherlands	2019 – 2022	F	Public health indicators (Health expectancy, DALYs), mathematical models and statistical methods, nutritional cancer epidemiology, socio-economic and geographic differentials in health, cost-efficacy of preventive interventions

Name	Country	Term of office	Gender	Field of expertise
James Robert Cerhan	USA	2019 – 2022	Μ	Environmental, lifestyle, genetic and biologic factors in the etiology of lymphomas as well as myeloid, breast, endometrial, colorectal and prostate cancers, lifestyle, genetic, tumour/microenvironment and treatment factors in lymphoma patients that predict outcomes and quality of life
Janne Mikael Pitkäniemi	Finland	2019 – 2022	Μ	Biostatistics, epidemiology, statistical methods in genetic epidemiology, cancer registration
Sabine Rohrmann	Switzerland	2019 – 2022	F	Diet/lifestyle and cancer risk, energy metabolism and components of the metabolic syndrome and their associations with cancer risk, factors influencing progression and survival of cancer patients
Anne Tjønneland	Denmark	2019 – 2022	F	Nutritional and cancer epidemiology
Kazem Zendehdel	Iran I.R.	2019 – 2022	Μ	Cancer epidemiology, cancer registration, implementation science and public health programmes, cancer prevention and early detection programmes, molecular and genetic epidemiology, clinical epidemiology, population-based survival, disease registry programmes
Karima Bendahhou	Morocco	2020 – 2023	F	Epidemiology and statistics
Tone Bjørge	Norway	2020 – 2023	F	Cancer and metabolic syndrome, micronutrient, birth characteristics among children and adolescents, pregnancy and maternal cancer, long-term consequences/adverse health effects of cancer in childhood and adolescence, cervical cancer epidemiology, screening, global burden of diseases
Gunilla Enblad	Sweden	2020 – 2023	F	Clinical and tumour biological studies of malignant lymphomas. Immunotherapy
William Gallagher	Ireland	2020 – 2023	Μ	Molecular oncology, precision medicine, breast cancer, prostate cancer, melanoma, next- generation sequencing technology, biomarker validation, molecular pathology, diagnostic assays, preclinical evaluation of novel anti-cancer agents

Name	Country	Term of office	Gender	Field of expertise
Ulrike Haug	Germany	2020 – 2023	F	Cancer epidemiology, pharmaco- epidemiology and molecular epidemiology, evaluation of molecular markers for early cancer detection and colorectal cancer screening
Sergey Ivanov	Russian Federation	2020 – 2023	Μ	Oncology, medical radiology, urology
Ravi Mehrotra	India	2020 – 2023	Μ	Cancer prevention, epidemiology, pathology and public health
Péter Nagy	Hungary	2020 – 2023	Μ	Oncogenesis, tumour progression, immune response/suppression and development of resistance to current therapies
Jong Bae Park	Republic of Korea	2020 – 2023	М	MicroRNA, mechanisms of carcinogenesis
Pietro Pichierri	Italy	2020 – 2023	М	Experimental and computational carcinogenesis

4. In accordance with Article VI.2 of the Agency's Statute, the Governing Council is requested to select new members to be appointed to the Scientific Council from the attached list of experts, one each from Australia, Belgium, Japan, Spain and the UK.

AUSTRALIA	BELGIUM
Professor Louisa Gordon QIMR Berghofer Medical Research Institute Royal Brisbane Hospital, Q4029, Brisbane	Dr Marc Arbyn Coordinator Unit Cancer Epidemiology – Belgian Cancer Centre
Field: Health economics, early detection, cancer intervention, decision-analytic modelling.	1050 Brussels Field: Obstetrics, gynecology, human papillomavirus, cancer screening and
Professor Caroline Miller Director, Health Policy Centre South Australian Health and Medical Research Institute (SAHMRI)	control, policy development, health- economic modelling.
Field: Tobacco control, primary and secondary cancer prevention, public health.	

JAPAN	SPAIN
Dr Manami Inoue Chief, Division of Prevention Center for Public Health Science National Cancer Center, Tokyo	Dr Ferrán Catalá National School for Health Instituto de Salud Carlos III, Madrid Field: Cancer epidemiology, public health,
 Field: Cancer epidemiology, cancer registry methodology. Dr Yasushi Yatabe Department of Diagnostic Pathology National Cancer Center, Tokyo Field: Human pathology and tumour diagnostics. 	health economics. Dr Iñaki Imaz Spanish HTA Instituto de Salud Carlos III, Madrid Field: Public Health, health economics, health technology.
 UK Professor Kalipso Chalkidou Centre for Global Development Westminster, London Field: Global health policy, health technology, healthcare coverage, epidemiology. Professor Rosalind Anne Eeles The Institute of Cancer Research Sutton, London Field: Clinical oncology, genetics, screening. 	

NB: The *curricula vitae* will be distributed to Governing Council members only.